Cargando…
Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
Aims/Introduction: When monotherapy with an oral hypoglycemic agent (OHA) is not sufficiently effective for blood glucose control, combination therapy with OHA having different mechanisms of action might be indicated. Materials and Methods: In the present study, we compared the efficacy of two opt...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014920/ https://www.ncbi.nlm.nih.gov/pubmed/24843485 http://dx.doi.org/10.1111/j.2040-1124.2010.00082.x |
_version_ | 1782315258766950400 |
---|---|
author | Katsuno, Tomoyuki Watanabe, Nobuaki Nagai, Etsuko Okazaki, Kazumi Yokoyama, Ariko Hamaguchi, Tomoya Miyagawa, Jun‐ichiro Namba, Mitsuyoshi |
author_facet | Katsuno, Tomoyuki Watanabe, Nobuaki Nagai, Etsuko Okazaki, Kazumi Yokoyama, Ariko Hamaguchi, Tomoya Miyagawa, Jun‐ichiro Namba, Mitsuyoshi |
author_sort | Katsuno, Tomoyuki |
collection | PubMed |
description | Aims/Introduction: When monotherapy with an oral hypoglycemic agent (OHA) is not sufficiently effective for blood glucose control, combination therapy with OHA having different mechanisms of action might be indicated. Materials and Methods: In the present study, we compared the efficacy of two options in type 2 diabetes mellitus patients whose blood glucose had not been well controlled with mitiglinide (30 mg/day) alone. A total of 20 patients were included in the study and divided into two groups: group A, in which mitiglinide was given concomitantly with the α‐glucosidase inhibitor voglibose (0.6 mg/day); and group B, in which a double dose of mitiglinide was given (60 mg/day). Twelve weeks after changing the medication, HbA(1c), glycoalbumin and 1,5‐anhydroglucitol (1,5‐AG) were measured. In addition, at weeks 0 and 12, a meal tolerance test was carried out, and plasma glucose, insulin, glucagon, active glucagon‐like peptide‐1 (GLP‐1) and total glucose‐dependent insulinotropic polypeptide levels were measured. Results: The plasma level of 1,5‐AG improved in both groups at week 12. In group A, the plasma insulin level significantly decreased and the plasma active GLP‐1 level significantly increased during the meal tolerance test at week 12; thus, bodyweight significantly decreased only in group A. Conclusions: Our findings suggested that concomitant administration of mitiglinide with voglibose could achieve better glycemic control, particularly in the postprandial period, without bodyweight gain and might have beneficial effects in type 2 diabetic patients at risk of macrovascular complications. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.0082.x, 2011) |
format | Online Article Text |
id | pubmed-4014920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40149202014-05-19 Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus Katsuno, Tomoyuki Watanabe, Nobuaki Nagai, Etsuko Okazaki, Kazumi Yokoyama, Ariko Hamaguchi, Tomoya Miyagawa, Jun‐ichiro Namba, Mitsuyoshi J Diabetes Investig Articles Aims/Introduction: When monotherapy with an oral hypoglycemic agent (OHA) is not sufficiently effective for blood glucose control, combination therapy with OHA having different mechanisms of action might be indicated. Materials and Methods: In the present study, we compared the efficacy of two options in type 2 diabetes mellitus patients whose blood glucose had not been well controlled with mitiglinide (30 mg/day) alone. A total of 20 patients were included in the study and divided into two groups: group A, in which mitiglinide was given concomitantly with the α‐glucosidase inhibitor voglibose (0.6 mg/day); and group B, in which a double dose of mitiglinide was given (60 mg/day). Twelve weeks after changing the medication, HbA(1c), glycoalbumin and 1,5‐anhydroglucitol (1,5‐AG) were measured. In addition, at weeks 0 and 12, a meal tolerance test was carried out, and plasma glucose, insulin, glucagon, active glucagon‐like peptide‐1 (GLP‐1) and total glucose‐dependent insulinotropic polypeptide levels were measured. Results: The plasma level of 1,5‐AG improved in both groups at week 12. In group A, the plasma insulin level significantly decreased and the plasma active GLP‐1 level significantly increased during the meal tolerance test at week 12; thus, bodyweight significantly decreased only in group A. Conclusions: Our findings suggested that concomitant administration of mitiglinide with voglibose could achieve better glycemic control, particularly in the postprandial period, without bodyweight gain and might have beneficial effects in type 2 diabetic patients at risk of macrovascular complications. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.0082.x, 2011) Blackwell Publishing Ltd 2010-11-22 2011-06-05 /pmc/articles/PMC4014920/ /pubmed/24843485 http://dx.doi.org/10.1111/j.2040-1124.2010.00082.x Text en © 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd |
spellingShingle | Articles Katsuno, Tomoyuki Watanabe, Nobuaki Nagai, Etsuko Okazaki, Kazumi Yokoyama, Ariko Hamaguchi, Tomoya Miyagawa, Jun‐ichiro Namba, Mitsuyoshi Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
title | Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
title_full | Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
title_fullStr | Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
title_full_unstemmed | Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
title_short | Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
title_sort | comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014920/ https://www.ncbi.nlm.nih.gov/pubmed/24843485 http://dx.doi.org/10.1111/j.2040-1124.2010.00082.x |
work_keys_str_mv | AT katsunotomoyuki comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT watanabenobuaki comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT nagaietsuko comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT okazakikazumi comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT yokoyamaariko comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT hamaguchitomoya comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT miyagawajunichiro comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus AT nambamitsuyoshi comparisonofefficacyofconcomitantadministrationofmitiglinidewithvogliboseanddoubledoseofmitiglinideinpatientswithtype2diabetesmellitus |